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Open access under CC BY licenseapping protein interactions by immunoprecipitation is limited by the availability of antibodies recog-
izing available native epitopes within protein complexes with sufﬁcient afﬁnity. Here we demonstrate a
alable approach for generation of such antibodies using phage display and afﬁnity maturation. We com-
ined antibody variable heavy (VH) genes from target-speciﬁc clones (recognizing Src homology 2 (SH2)
omains of LYN, VAV1, NCK1, ZAP70, PTPN11, CRK, LCK, and SHC1) with a repertoire of 108 to 109 new
ariable light (VL) genes. Improved binders were isolated by stringent selections from these new
hain-shufﬂed’’ libraries. We also developed a predictive 96-well immunocapture screen and found that
nly 12% of antibodies had sufﬁcient afﬁnity/epitope availability to capture endogenous target from
sates. Using antibodies of different afﬁnities to the same epitope, we show that afﬁnity improvement
as a key determinant for success and identiﬁed a clear afﬁnity threshold value (60 nM for SHC1) that
ust be breached for success in immunoprecipitation. By combining afﬁnity capture using matured anti-
odies to SHC1 with mass spectrometry, we identiﬁed seven known binding partners and two known
C1 phosphorylation sites in epidermal growth factor (EGF)-stimulated human breast cancer epithelial
lls. These results demonstrate that antibodies capable of immunoprecipitation can be generated by
ain shufﬂing, providing a scalable approach to mapping protein–protein interaction networks.
 2011 Elsevier Inc.Open access under CC BY license.The creation of a resource of binders to all proteins in the pro- Antibody phage display, ﬁrst described two decades ago [11], is a
p
li
o
w
sc
m
o
an
st
d
1 Abbreviations used: SH2, Src homology 2; pTyr, phosphorylated tyrosine; scFv,
single chain variable fragment; VH, variable heavy; VL, variable light; MS, mass
spectrometry; EGF, epidermal growth factor; PCR, polymerase chain reaction; DTT,
dithiothreitol; BSA, bovine serum albumin; ELISA, enzyme-linked immunosorbent
assay; PBS, phosphate-buffered saline; PBSM, 2% milk powder in PBS; PBST, PBS and
0.1% Tween 20; IP-ELISA, immunoprecipitation ELISA; RU, response units; PMSF,ome together with their splice variants and posttranslational
odiﬁcations would be of great value to the research community
,2]. Application of such antibodies to afﬁnity capture of protein
mplexes (immunoprecipitation) would enable the characteriza-
on of cellular signaling networks in response to various stimuli.
urrent methods require the artiﬁcial ‘‘tagging’’ of proteins that
ay alter their activity and cellular location, whereas the use of
inders to native proteins allows one to directly observe unmodi-
ed proteins. There are several initiatives and proposals relating
genome-wide antibody generation [1,3–5]. The ability to gener-
e large sets of antibodies validated for use in immunoprecipita-
on represents an ambitious goal that would nonetheless be of
ormous value to the research community in understanding
rotein interaction networks.
This goal can best be achieved by screening large recombinant
hage [6,7], yeast [8,9], or ribosome [10] display libraries, which
a faster and more scalable approach than animal immunization.ph
ge
re
.owerful method for selecting novel binders from large antibody
braries by linking the binding properties of an antibody displayed
n the surface of ﬁlamentous bacteriophage to the encoding DNA
ithin the bacteriophage. As an alternative to antibodies, other
affolds have been used with phage display to generate binding
olecules, including combinatorial peptides [12], the Z domain
f protein A [13], the ﬁbronectin type III domain [14], and designed
kyrin repeat proteins [15].
In a recent international collaboration, we and others demon-
rated the feasibility of generating research reagents by phage
isplay by targeting a group of 20 Src homology 2 (SH2)1enylmethylsulfonyl ﬂuoride; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide
l electrophoresis; MRM, multiple reaction monitoring; SPR, surface plasmon
sonance; EGFR, EGF receptor.
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signal transduction processes through their ability to bind phosphor-
ylated tyrosine (pTyr)-containing polypeptides [18,19]. In humans,
there are 120 SH2 domains found within 110 distinct proteins that
represent several different protein classes, including kinases, phos-
phatases, adapters, and transcription factors [20]. The SH2 domain
consists of approximately 100 amino acids that fold into an antipar-
allel b-sheet ﬂanked by two a-helices. Binding speciﬁcity of the SH2
domain is typically mediated by the 3–6 amino acids C terminal to
the pTyr in the target sequence [21,22]. Given their widespread role
in signal transduction and the availability of many characterized
antibodies, in this study we focused on eight different SH2 domain
proteins: LYN, VAV1, NCK1, ZAP70, PTPN11, CRK, LCK, and SHC1.
For more detailed quantitative studies, we concentrated on the
SH2 domain-containing protein SHC1. SHC1 is a prototypic scaffold
protein that is essential for cancer progression [23]. It links activated
receptor protein tyrosine kinases to the Ras-MAPK pathway and is a
mediator of cell responsiveness to different external stimuli involv-
ing G protein-coupled receptors, immunoglobulin receptors, inte-
grins, and non-receptor tyrosine kinases [24]. SHC1 has been
shown to direct tissue morphogenesis during development [24]
and encodes three splice variants of 46 kDa (p46SHC1), 52 kDa
(p52SHC1), and 66 kDa (p66SHC1). Overexpression of p66SHC1
accelerates ES cell neural induction and modulates the Wnt/b-cate-
nin pathway [25].
The availability of immunoprecipitation reagents to these and
other signaling molecules would be of enormous beneﬁt for
studying signaling interactions and dynamics either individually
or at a systems biology level. Despite the long history of the use
of antibodies in immunoprecipitation, and despite the importance
of the technique, there have been no studies examining the rela-
tionship between antibody afﬁnity and performance in immuno-
precipitation. Immunoprecipitation is a particularly challenging
application for antibodies because it requires afﬁnity capture and
retention of native proteins and their complexes present at
relatively low concentrations in cells or tissues. Given these
requirements, we anticipated that high afﬁnity would be a crucial
determinant of success and sought to improve the afﬁnity of
antibodies emerging from phage display selections. Following the
initial selection of antibodies recognizing SH2 domains [17], we
employed ‘‘chain-shufﬂing’’ to create secondary gene-speciﬁc
libraries.
In our antibody display library, antibodies are presented in the
form of single chain variable fragments (scFvs), where the heavy
chain variable region genes (VH) and light chain variable region
genes (VL) are joined by a ﬂexible linker peptide. Although the ini-
tial phage antibody selections [17] were performed with a very
large antibody library consisting of more than 1010 clones [7], we
reasoned that any VH will have paired with a limited number of
VL partners (and vice versa) and that each might not have found
its optimal partner from the available repertoires. Therefore, we
employed chain shufﬂing as a simple method for creating second-
ary diversiﬁed libraries from individual antibodies from which we
could select higher afﬁnity variants. Because the greatest diversity
resides within the VH region, we retained selected VH genes and
shufﬂed these with a repertoire of VL genes. Therefore, we created
diversiﬁed libraries to eight targets in parallel by cloning selected
mixes of VH genes from primary selections [17]. These libraries
were subjected to stringent selections using limiting concentra-
tions of biotinylated antigen.
The availability of the target epitope is an important factor in
determining success in immunoprecipitation. With this in mind,
we developed a novel 96-well immunocapture screen to rapidly
identify binders recognizing available epitopes with sufﬁcient
afﬁnity to capture low levels of endogenous SHC1 in a breast
cancer epithelial cell line. The afﬁnities and off-rates of a panel ofanti-SHC1, all sharing the same VH gene, were measured, and these
correlated with their ability to work in immunoprecipitation. We
demonstrated the use of our anti-SHC1 antibodies in immunopre-
cipitation coupled to mass spectrometry (MS) to identify known
binding partners of SHC1 during epidermal growth factor (EGF)
signaling.Materials and methods
Generation of scFv libraries by chain shufﬂing
The VH region of selected scFvs speciﬁc to the SH2 domains
(LYN, VAV1, NCK1, ZAP70, PTPN11C, CRK, LCK, and SHC1) were
polymerase chain reaction (PCR) ampliﬁed from pSANG10-TEV
plasmid DNA [17] with the primers pSANG10-PelB (CGCTGCCC
AGCCGGCCATGG) and HLINK (ACCGCCAGAGCCACCTCCGCC). The
PCR reactions consisted of primers (0.5 lM), 2 Qiagen Hot Start
Taq PCR mix (25 ll), and plasmid DNA (100 ng) in a total volume
of 50 ll. The set of ampliﬁed VH genes for each target antigen were
pooled and puriﬁed by Qiagen spin column, and inserts (15 lg)
were digested with NcoI (40 U) and XhoI (60 U) in 200 ll of NEB
buffer 2 (50 mM NaCl, 10 mM Tris–HCl [pH 7.9], 10 mM MgCl2,
1 mM dithiothreitol [DTT], and 0.1 mg/ml bovine serum albumin
[BSA]) for 3 h at 37 C. Digested inserts were puriﬁed by Qiagen
spin column and ligated to the NcoI/XhoI cut pSANG4 vector har-
boring the naive VL j- and k-chain libraries [7]. Ligation reactions
contained VH insert (1 lg), pSANG4 vector (2.5 lg), 50 mM Tris–
HCl (pH 7.5), 10 mM MgCl2, 1 mM ATP, 10 mM DTT, and T4 DNA
ligase (1000 U, New England Biolabs) in a total volume of 125 ll
and were incubated at 16 C for 16 h. Ligation reactions were
phenol–chloroform extracted by the addition of 175 ll of 10 mM
Tris–HCl (pH 8.0) to each ligation reaction, followed by extraction
with 300 ll of phenol–chloroform–isoamylalcohol (25:24:1), and
then vortexed and spun at 15,600g (2 min, 4 C). The top aqueous
layer was transferred to a fresh microfuge tube containing 280 ll
of chloroform, vortexed, and spun at 15,600g (2 min, 4 C), and
the top aqueous layer was transferred to a fresh microfuge tube
containing 1/10 volume (20 ll) of 3 M potassium acetate (pH
7.0). To this, 2.5 volumes (500 ll) of chilled 100% ethanol was
added, incubated on ice for 10 min, spun at 15,600g (10 min,
4 C), supernatant decanted, pellet washed with 600 ll of chilled
75% ethanol, spun at 15,600g (5 min, 4 C), supernatant decanted,
pellet air dried at 37 C for 10 min, and dissolved in 4 ll of
10 mM Tris–HCl (pH 8.0). Here 2 ll of ligation reaction was used
to electroporate 40 ll of electrocompetent TG1 cells in duplicate
(Bio-Rad MicroPulser, EC1 channel), followed by the addition of
2 ml of SOC medium and incubation at 37 C for 40 min. Cells were
plated on 2 TY agar plates containing ampicillin (100 lg/ml) and
glucose (2%). Dilutions of the transformation were also plated to
determine library size, which ranged from 1.5  108 to 2  109
clones, with 77–93% of the transformants being positive for inser-
tion scFv encoding insert, as determined by colony PCR.Phage display selections, subcloning scFv populations into an
expression vector, and primary ELISA
Rescue of phage particles from the chain-shufﬂed libraries and
two rounds of selections against the eight SH2 domains were as de-
scribed previously [7] except that selections employed biotinylated
antigens (0.1–100 nM) that were captured with 25 ll of streptavi-
din-coated Dynabeads (Invitrogen, cat. no. M-280). Selected scFv
populations were subcloned en masse from the phagemid vector,
pSANG4, into the expression plasmid, pSANG-TEV-3F, which ex-
presses scFvs with a six-histidine tag, a cleavage site for tobacco
etch virus (TEV) protease, and three tandem copies of the FLAG
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Escherichia coli grown in 96-well plates and primary enzyme-
linked immunosorbent assay (ELISA) screening has been described
previously [17].
Inhibition polyclonal phage ELISA
To compare the relative binding strengths of the scFvs, which
were displayed on phage particles, an inhibition phage ELISA was
performed. First, phage dilutions were incubated with antigen-
coated wells to determine the optimal phage concentration to
use for the inhibition assays. Black, 96-well ﬂat-bottom, Maxisorp
polystyrene plates (Nunc, cat. no. 43711) were coated with antigen
(2.5 lg/ml) in phosphate-buffered saline (PBS) overnight, blocked
with 2% milk powder in PBS (PBSM) for 1 h, and then incubated
with serial dilutions (2–128 in PBSM) of speciﬁc phage popula-
tions for 1 h. Plates were washed three times with PBS and 0.1%
Tween 20 (PBST), washed three times with PBS, and then incubated
with anti-M13 antibody (1 lg/ml in PBSM, GE Healthcare). After
1 h, plates were washed and bound phage particles were detected
with a europium-labeled anti-mouse secondary antibody (Perkin–
Elmer) in a DELFIA time-resolved ﬂuorescence assay. A phage con-
centration, giving a signal of between 10,000 and 20,000 europium
ﬂuorescence units, was then used in the inhibition assay, where a
ﬁxed concentration of phage particles was preincubated with vary-
ing concentrations of antigen (1–1000 nM) at 4 C in PBSM prior to
incubation with antigen-coated wells for 30 min. Detection was as
described above.
scFv inhibition ELISA and IP-ELISA
scFv inhibition ELISA was used to afﬁnity rank individual
clones. scFvs were expressed in bacteria grown in 96-well plates
using autoinduction media [26], and culture supernatants (diluted
2- to 60-fold in PBSM) were incubated with antigen-coated plates
and detected as above to identify suitable dilutions of clone sets
for inhibition assays. The scFv inhibition assay was as described
above for the inhibition phage ELISA except that ﬁxed antigen con-
centrations were employed (316, 100, and 31.6 nM) and detection
employed a europium-labeled anti-FLAG antibody (Sigma). For
immunoprecipitation ELISA (IP-ELISA), 50 ll (5 lg/ml) of anti-
FLAG antibody in PBS (Sigma) was used to coat polystyrene
96-well plates overnight, followed by blocking in PBSM. After
washing three times with PBST and three times with PBS, 50 ll
of scFvs was added to each well (consisting of 25 ll of culture
supernatant and 25 ll of 2 PBSM) and incubated for 1 h to per-
mit capture of the scFvs via their FLAG epitope tags. Plates were
washed, and then 50 ll of cell lysate (prepared as described be-
low) was added. The plates were incubated overnight at 4 C and
washed. Bound endogenous full-length SHC1 was detected by
the addition of 50 ll (0.5 lg/ml) of anti-SHC1 rabbit polyclonal
antibody (BD Biosciences, cat. no. 610085) in PBSM. Subsequently,
the plates were washed, followed by the addition of 50 ll
(0.5 lg/ml) of europium-labeled goat anti-rabbit antibody
(Perkin–Elmer).
Expression and puriﬁcation of scFvs
Single chain antibodieswere initially expressed from the expres-
sion vector pSANG-TEV-3F [17] and subsequently frompSANG10-3F
[27], which gives a superior expression yield. Antibodies were
expressed in E. coli BL21(DE3) or the T-phage-resistant E. coli
BL21(DE3) V2R pRARE2, which was kindly provided by Douglas
Cossar and Peter Loppnau (Structural Genomics Consortium,
Toronto, Canada). Details regarding bacterial expression of scFvs at
a 500-ml scale in autoinduction media [26], periplasmic extraction,and afﬁnity puriﬁcation were as described previously [27]. Selected
scFvs were expressed as Fc fusions by cloning into an Fc expression
vector [28], transient transfectionofHEK293E cells [29], followedby
afﬁnity puriﬁcation from culture supernatants.BIAcore kinetic analysis
Size exclusion chromatography revealed that the puriﬁed scFvs
were a mixture of monomer and dimer (data not shown). There-
fore, to enable monovalent binding kinetics, scFvs were subcloned
into the vector pSANG10-HC (see supplementary material), which
adds a His10-CLAMP tag [30] onto the C terminus of the scFvs.
Expression and puriﬁcation of scFvs were as described above. The
‘‘afﬁnity clamp’’ protein (ePDZ-b1) was expressed and puriﬁed as
reported previously [30] and covalently attached (70 response
units [RU]) to a dextran-coated CM5 sensor chip using standard
EDC/NHS (N-ethyl-N0-(dimethylaminopropyl) carbodiimide/N-
hydroxysuccinimide) chemistry [31]. The running buffer for all
BIAcore experiments was ﬁltered PBS (Dulbecco A, Oxoid, cat. no.
BR0014G) supplemented with 0.05% Tween 20. Prior to each ki-
netic experiment, a conditioning step was performed where the
regeneration buffer (10 mM glycine, pH 1.5) was injected (15 ll,
30 ll/min) over the sensor chip surface. For each kinetic cycle,
scFvs (150 nM, 15 ll injection, 5 ll/min ﬂow rate) were bound to
the immobilized ePDZ-b1 via the CLAMP tag. After a 2-min stabil-
ization period (5 ll/min ﬂow rate), increasing concentrations of
puriﬁed SHC1 (see Supplementary Fig. 1 in the supplementary
material for concentration ranges) were injected (30 ll) into the
BIAcore T100 at a 30-ll/min ﬂow rate. Binding and dissociation
were monitored over 60- and 120-s windows, respectively. After
each cycle, 10 mM glycine (pH 1.5) was used to strip the scFvs/
SHC1 off the sensor chip (15 ll, 30 ll/min). The binding proﬁles
were evaluated using the global ﬁtting analysis with BIAevaluation
T100 software and a 1:1 interaction model.Immunoprecipitation of endogenous SHC1 from human breast cancer
epithelial cell line MDA-MB231
Adherent MDA-MB231 cells were propagated in 145-mm tissue
culture dishes in RPMI 1640 medium (PALL), which was supple-
mented with 5% fetal bovine serum (FBS). When cells reached
70–80% conﬂuency, they were washed with PBS (5 ml/dish),
scraped off the plate with PBS (2 ml/dish), and pelleted by centri-
fugation (200g, 4 min). Cells (107/dish) were resuspended
(2 ml/dish) in NP-40 lysis buffer (50 mM Hepes–KOH [pH 8.0],
100 mM KCl, 2 mM ethylenediaminetetraacetic acid [EDTA], 0.5%
NP-40, 50 mMNaF, and 2 mMDTT), which was supplemented with
protease and phosphatase inhibitors (50 mM b-glycerolphosphate,
10 lg/ml aprotinin, 10 lg/ml leupeptin, 1 mM vanadate, and 1 mM
phenylmethylsulfonyl ﬂuoride [PMSF]) and incubated on ice for
10 min. Lysates were cleared by centrifugation (25,000g, 20 min).
FLAG-tagged anti-SHC1 scFv antibody (2 lg) was prebound to
FLAG-M2 agarose (20 ll, 50% slurry, Sigma) in 400 ll of lysis buffer
for 30 min. The resin was washed three times prior to the addition
of 1 ml of clariﬁed MDA-MB231 cell lysate. The cell lysate was
incubated with resin for 1 h at 4 C (by end-over-end mixing),
and the resin was washed four times with 1 ml of NP-40 lysis buf-
fer. Then 2 volumes of sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) loading buffer (50 ll) was added to
the washed resin. The immunoprecipitates were heated to 95 C
for 5 min and resolved by 4–20% SDS–PAGE, followed by Western
blotting to polyvinylidene ﬂuoride (PVDF) membrane. Blots were
probed with rabbit polyclonal anti-SHC1 (1:2000, BD Biosciences)
and goat anti-rabbit IR800 (1:15,000, LICOR). Immunoprecipitation
with adherent HEK293 cell lysates was as described above except
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Eagle’s medium (DMEM, PALL).
Immunoprecipitation of endogenous SHC1 present in lysates of
ﬁbroblasts
Approximately 5 million Rat2 ﬁbroblasts were stimulated with
EGF (100 ng/ml) for 3 min, washed twice with cold PBS, and lysed
in 1 ml of lysis buffer (50 mM Hepes [pH 8.0], 100 mM KCl, 0.5%
NP-40, 10% glycerol, 0.5 mM ethyleneglycoltetraacetic acid [EGTA],
1 mM Na3VO4, 2.5 mM NaPPi, 1 mM PMSF, and protease inhibitors
[Sigma]). Cell debris was removed by centrifugation (14,000g,
30 min). Nuclear-free lysate was subsequently incubated with rab-
bit polyclonal anti-SHC1 antibody (BD Biosciences) that was pre-
bound to protein A agarose (40 ll, 10% slurry, Generon) or with
FLAG-tagged anti-SHC1 scFv antibody that was prebound to
FLAG-M2 agarose (50% slurry, Sigma) for 6 h. Immunoprecipitants
were washed six times with lysis buffer and twice with 50 mM
ammonium bicarbonate (pH 8.0), followed by on-bead tryptic
digestion with 0.4 lg of trypsin (Promega) at 37 C for 6 h. The
resulting peptide mixture was transferred to a new Eppendorf tube
for acidiﬁcation and drying.
MS analysis
Dried peptides were reconstituted with 5% formic acid. MS
analysis was performed on a hybrid triple quadrupole/ion trap
mass spectrometer (4000 Q Trap, ABI/MDS Sciex). Chromato-
graphic separations of peptides were carried out on a nano-LC sys-
tem (Eksigent) coupled to a 100-lm (i.d.) fused-silica column
packed with 5 lm Zorbax C18 as the trap column and a 75-lm
(i.d.) fused-silica column packed with 3.5 lm Zorbax C18 as the
column. A micro-Tee and injection valves were used to connect
both columns. Peptides were separated with a linear gradient from
2 to 30% acetonitrile in 90 min at a ﬂow rate of 300 nl/min. An in-
house-developed and validated multiple reaction monitoring
(MRM) assay, speciﬁcally designed to target SHC1 binding part-
ners, was used to detect SHC1 and its interacting proteins in sam-
ples. A full tandem MS (MS/MS) spectrum for each observed
peptide was also acquired for sequence validation. Acquired raw
ﬁles were converted to MGF format and searched against the
Ensembl Rat database (release version 49) using Mascot (version
2.1). The search result in DAT format were subsequently processed
with Peptide and Protein Prophet embedded in Scaffold (Proteome
Software) using a protein identiﬁcation threshold at more than
90% conﬁdence.Results
Creation of chain-shufﬂed libraries and selection
Previous selections on the SH2 domains of LYN, VAV1, NCK1,
ZAP70 (tandem domains), PTPN11C (the C-terminal domain of
PTPN11), CRK, LCK, and SHC1 [17] identiﬁed between 15 and 43
clones per antigen that bound only to their appropriate antigen
among a set of 20 SH2 domains. VH genes were PCR ampliﬁed from
these and combined in antigen-speciﬁc oligoclonal mixes, and
shufﬂed libraries were prepared by cloning the products into a
phage display vector harboring the VL population used in the
construction of the original phage display library [7]. Chain-shufﬂed
libraries, typically containing more than 1  109 clones, were afﬁn-
ity selected under increasing stringency using limiting amounts of
biotinylated antigens in solution [7]. The afﬁnities of the selected
populations were approximated using polyclonal phage in inhibi-
tion ELISA experiments (Fig. 1). A signiﬁcant improvement in aver-age afﬁnity of the antibody populations was achieved from
stringent selection of the chain-shufﬂed library using soluble biotin-
ylated antigen compared with selection on the original naive phage
display library (unshufﬂed library) carried out by ‘‘panning’’ on
immobilized antigen [17]. For comparison, selection of the shufﬂed
librarywas also carriedoutbypanningondirectly immobilizedanti-
gen in some cases. Selection under these lower stringency condi-
tions also led to an improvement in average afﬁnity compared
with the original unshufﬂed selections. The best results, however,
were obtained from the combination of the shufﬂed library and
stringent selection conditions with soluble antigen, as illustrated
for VAV1 (Fig. 1A). This is also reﬂected in the monoclonal ELISA re-
sults for VAV1 represented in Fig. 2A and D.
Screening for high-afﬁnity anti-SH2 scFvs
For monoclonal screening, the inserts from the selected popu-
lation of phage particles were subcloned into a plasmid vector
optimized for soluble antibody expression [27] and transformed
into E. coli BL21(DE3), and 96 clones were picked for evaluation
by ELISA (Fig. 2). The primary ELISA screens for all eight SH2 do-
mains demonstrated improved results using the chain-shufﬂed li-
braries (Fig. 2) compared with the original selections using the
unshufﬂed library [17]. For example, the proportion of clones
exceeding an ELISA signal of 10,000 U increased from 6 to 69
for the ZAP70 selection using the shufﬂed library (Fig. 2G and J).
Because the signal levels in ELISA are a function of both the
expression level of the antibody and its binding strength for the
target antigen, inhibition ELISAs [32] were performed with puri-
ﬁed scFvs to help identify the highest afﬁnity clones for each of
the eight SH2 domains (data not shown). Selected scFvs were
then expressed in E. coli, and periplasmic extracts were prepared
and afﬁnity puriﬁed. Surface plasmon resononance (SPR) mea-
surements indicated that afﬁnities in the low-nanomolar (nM)
range were achieved [1].
Sequence analysis revealed that the chain-shufﬂing process
had successfully generated new clones by partnering VH chains
with new VL chains, as summarized in Table 1. (Each selection
is given a number, and clones derived from that selection inherit
the selection number as the ﬁrst part of their name; e.g., clone
68_C01 is derived from selection 68 on ZAP70.) The greatest
diversity occurs within the CDR3 sequences of heavy and light
chains and for simplicity clones are grouped according to these
sequences. For example, the ZAP70 selection (selection 68) re-
sulted in 11 original VH chains now partnered with new VL chains
to give a total of 40 unique scFv sequences (from 48 sequenced).
Similarly, afﬁnity maturation of PTPN11C binders (selection 69)
resulted in a total of 6 VH chains now partnered with 27 different
VL chains. Selection on LYN (selection 65) resulted in a total of 4
VH chains now partnered with 10 different VL chains. The selec-
tions for VAV (selection 66), NCK1 (selection 67), CRK (selection
70), and LCK (selection 71) resulted in only 1 or 2 different VH
chains partnered with new VL chains.
To generate a large number of clones to analyze the relationship
between immunoprecipitation success and afﬁnity, we focussed on
SHC1. ELISAs were performed on 960 clones derived from the
chain-shufﬂed SHC library, and 607 were found to be positive in
ELISA. Of these, 155 clones with the strongest ELISA signals were
sequenced. Although 15 different VH genes were used in the shuf-
ﬂed library construction, sequencing revealed that only 5 of these
were represented in the top 155 clones (see Supplementary Table 1
in supplementary material). Diversity had been introduced by
partnering these 5 VH genes with 59 different VL chains based on
VL CDR3 sequence. The anti-SHC1 scFvs were subdivided into
‘‘clans’’ sharing the same VH gene. Clans 1–5 contained 1, 2, 9,
19, and 28 different VL chains, respectively.
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Fig.1. Improvement in antibody afﬁnity following chain shufﬂing. Inhibition ELISAs were conducted by preincubating polyclonal phage derived from two rounds of selection
with a range of antigen concentrations prior to incubation on antigen-coated wells. Bound phage populations were detected with anti-M13 antibody. Signal in ELISA from
these samples is expressed relative to the uninhibited control. Phage particles were derived from panning using either the original library (‘‘Unshufﬂed-PAN’’) or the shufﬂed
library (‘‘Shufﬂed-PAN’’) or by stringent selection on biotinylated antigen (‘‘Shufﬂed-Bio’’). Examples are shown for the SH2 domain target VAV1 (A), the C-terminal domain of
PTPN11C (B), and the ZAP70 tandem (C) and SHC1 (D) SH2 domains. Selection numbers, which are also used in clone names, are in parentheses.
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Success in immunoprecipitation is likely to be determined both
by antibody afﬁnity and the availability of the recognized epitope
in complexes of native protein. To examine the relationship
between afﬁnity and the potential for immunoprecipitation, a sim-
ple 96-well immunocapture assay was designed to identify anti-
bodies capable of capturing SHC1 from lysates of the breast
cancer epithelial cell line MDA-MB231 [33]. The assay involved
capture of the scFvs via an immobilized anti-FLAG antibody, fol-
lowed by capture of native SHC1 from MDA-MB231 lysates de-
tected using a polyclonal antibody. Using this assay format, the
top 155 binders raised against SHC1 were screened, and 19 (12%)
were found to capture endogenous SHC1 from cell lysates (see
Table 2, last column, for example signal intensities). A representa-
tive set of 20 positive and negative antibodies was then puriﬁed by
immobilized metal afﬁnity chromatography and used for immuno-
precipitation, followed by quantitative Western blotting (see
Fig. 3). There was an excellent correlation between the results ofthe immunocapture assay and immunoprecipitation/Western blot-
ting assays; all positive scFv clones from the former were also
strongly positive in the latter, demonstrating the value of the
plate-based assay for assessing large numbers of clones.
Efﬁciency of dimeric scFv–Fc fusions on immunoprecipitation
efﬁciency
To study whether dimerizing the scFvs would result in in-
creased efﬁciency in pulling down endogenous SHC1 from a cell ly-
sate, anti-SHC1 scFvs 72_1A01 and 72_1A10 were cloned into an Fc
expression plasmid and, expressed in HEK293E suspension cells
[28], and afﬁnity puriﬁed. Similar results in immunoprecipitation
efﬁciency were observed for both the mainly monomeric scFvs
and dimeric scFv–Fc fusions; clone 72_1A10 efﬁciently pulled
down endogenous SHC1, whereas clone 72_1A01 did not (Fig. 4).
If the target antigen is monomeric and in solution, increasing the
valency of the scFvs would not be expected to give an advantage
and efﬁciency of capture would be based on the monovalent
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Fig.2. Primary ELISA screen of chain-shufﬂed antibodies selected using each of the eight different SH2 domains. Afﬁnity selections against the different SH2 domains with the
eight chain-shufﬂed libraries took place under different conditions, and the optimal selections were determined based on polyclonal ELISA results (data not shown).
Populations were subcloned into an optimized expression vector, and 96 clones were picked and screened by ELISA. Binding of the scFvs to the immobilized SH2 domain was
quantiﬁed using europium-labeled anti-FLAG secondary antibody. A graph is shown for each of the 12 selections (A–L), plotting the time-resolved ﬂuorescence signal in
intensity units (y axis) for each scFv (x axis). The graph titles indicate the selection conditions employed (e.g., PAN1–PAN2 indicates two rounds of selections were performed
with antigen immobilized on polystyrene wells, Bio100–Bio10 indicates that the ﬁrst selection round was performed with 100 nM biotinylated antigen and the second round
was performed with 10 nM biotinylated antigen). The selection numbers, used to name the antibodies, are shown in parentheses.
Table 1
Selection summary.
Selection
number
Target Number of input
VH genes
Number of VH
genes used
Number of unique VL genes
and number sequenced
Number of output VL genes
(based on unique VL CDR3)
65 LYN 7 4 28 (29) 10
66 VAV1 6 1 30 (48) 9
67 NCK1 6 2 26 (44) 4
68 ZAP70 20 11 40 (48) 26
69 PTPN11C 12 6 42 (47) 27
70 CRK 1 1 33 (45) 7
71 LCK 12 2 22 (24) 18
72 SHC1 12 5 112 (155) 59
Note: Numbers sequenced are in parentheses.
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ever, if the target to be pulled down naturally existed as a multi-
meric complex. All pull-down experiments described here
employed antibody preconjugated to resin, potentially creating a
multivalent surface and an avidity effect even when the original
antibody is monovalent. Although evidence is lacking for the exis-
tence of SHC1 dimers or multimers, it is known that EGF stimula-
tion leads to a microclustering of EGF receptor (EGFR) and, by
implication, its signaling complex [34]. Therefore, multivalent
binding reagents may be expected to be more efﬁcient thanmonovalent reagents for immunoprecipitation of the SHC1 signal-
ing complex.
Relationship among afﬁnity, off-rate, and utility in
immunoprecipitation
The availability of related antibodies within a clan that share the
same heavy chain variable domain provides an opportunity to
examine in isolation the effect of afﬁnity on performance within a
single epitope group. Afﬁnities were determined for 10 anti-SHC1
Table 2
BIAcore kinetic data and quantitative data from afﬁnity capture assay and quantitative Western blots showing percentage recovery in immunoprecipitation.
Note: Antibody names highlighted in green or red passed or failed immunoprecipitation, respectively. Parental scFvs have the preﬁx 58, and afﬁnity matured scFvs have the
preﬁx 72. Global ﬁts were performed on the full 60 s of the association phase and the initial 20 s of the dissociation phase (see Supplementary Fig. 1). The last column (IP-
ELISA) shows the signals obtained in the immunoprecipitation ELISA (see Materials and methods), which measures the ability of immobilized scFvs to bind endogenous SHC1
from a breast cancer epithelial cell lysate. (For interpretation of the references to color in this table note, the reader is referred to the Web version of this article.)
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(see Supplementary Table 2 for full sequence alignment). A clear
correlation was observed between the afﬁnity/dissociation rate
and efﬁciency in capturing a target from a cell lysate by immuno-
precipitation. For example, the parental anti-SHC1 scFv clone
58_E05 failed in immunoprecipitation (Fig. 3A) but was surpassed
by a chain-shufﬂed derivative 72_2B01 (Fig. 3B) with a 59-fold
improvement in afﬁnity and a 3.2-fold reduction in off-rate (Ta-
ble 2). Of the eight chain-shufﬂed derivatives, six were positive in
immunoprecipitation experiments and these had KD values below
60 nM and off-rates of less than 0.1 s1. There appears to be a rela-
tively steep cutoff for afﬁnity/off-rate in determining success and
failure in immunoprecipitation experiments (Fig. 5A and B). One
explanation is that extensive wash steps are performed to remove
nonspeciﬁc binders, prior to analysis, during a typical immunopre-
cipitation experiment. The proportion of complex remaining over
time was modeled using three different off-rates and assuming a
simple exponential decay curve [35]. Exponential equations are
commonly used tomodel the processes of radioactive isotope decay
or of a ligand dissociating from its receptor. In the latter case, the
rate of dissociation is proportional to the initial concentration. We
adopted this exponential model to simulate the dissociation of an
antibody from its target antigen. Fig. 5C shows on a logarithmic
scale that a relativelymodest change in off-rate can have a dramatic
effect, ranging over many orders of magnitude, on the proportion of
target that remains associated with the capture antibody at differ-
ent time points, providing an explanation for the sharp cutoff in the
relationship between afﬁnity and immunoprecipitation success.
Use of afﬁnity matured anti-SHC1 antibodies to map the EGFR/SHC1
signaling complex
The utility of antibodies in capturing endogenous proteins and
identifying associated binding partners was evaluated by immuno-
precipitation, followed by liquid chromatograph–mass spectrome-
try (IP/LC–MS) analysis. Multiprotein complexes mediated by SHC1
form an essential signaling network module downstream of the
activated EGFR tyrosine kinase. To identify SHC1-interacting part-
ners, EGF-stimulated Rat2 ﬁbroblasts were lysed and endogenous
SHC1 was afﬁnity captured with antibody 072_1A10. The recovery
of SHC1 and its binding partners was then investigated using an
MRM-based MS method employing procedures that we recently
developed to analyze such SHC1 complexes unpublished data:
Y.Z, C.Z, K.C, and T.P. This speciﬁc method allows MRM-initiated
detection and sequencing (MIDAS) [36] for sequence validation,
providing high conﬁdence detection of speciﬁed interactors. In this
case, a subset of seven SHC1-interacting partners was identiﬁed,
comprising a core multiprotein signaling network nucleatedaround SHC1 during EGF signaling. We observed all seven
interacting partners (EGFR, GRB2, SOS1, GAB1, PTPN11, PTPN12,
and AP2) as well as two known SHC1 phosphorylation sites
(pSer29 and pTyr313) (Supplementary Fig. 3 and Supplementary
Table 3). A total of 34 binary interactions for human SHC1, identi-
ﬁed in immunoprecipitation experiments, are listed in the IntAct
database [37], including those listed above. In this study, we may
have identiﬁed a subset of SHC1 interactions that occur relatively
early following activation of the EGFR signaling pathway. Based
on our quantitative analysis of the Shc1 signaling network unpub-
lished data: Y.Z, C.Z, K.C, and T.P. the proteins identiﬁed in this arti-
cle represent the most abundant and stable interactors of SHC1
downstream of EGFR signaling. In addition, the anti-SHC1 scFvs
are generated against the SH2 domain of SHC1 and, thus, may
interfere with some protein–protein interactions that require the
SHC1 SH2 domain. Finally, the known protein–protein interactions
mediated by SHC1 are pathway and cell type speciﬁc. For example,
nPKCd was identiﬁed as an SHC1 interactor in the IntAct database,
but only in the context of Bcr-Abl signaling in CML K562 cells [38].
Discussion
The combination of antibody afﬁnity capture coupled with MS
provides a powerful platform for mapping protein–protein interac-
tions. The widespread use of this technique, however, is limited by
the availability of suitable antibodies. Understanding the require-
ments for immunoprecipitation and increasing the availability of
such reagents would be of huge advantage in mapping protein
interaction networks, particularly if this could be applied in a
high-throughput manner. Several factors, including the properties
of the targeted epitope, determine the utility of individual antibod-
ies for immunoprecipitation. In techniques such as Western blot-
ting and immunohistochemistry, the antibody must recognize an
epitope, typically linear, that survives the denaturation conditions
used. In contrast, immunoprecipitation requires antibodies that
recognize the native proteins. Depending on the supramolecular
architecture of the protein complex, some epitopes will not be
accessible for antibody capture because they will be occluded by
other interacting proteins within the complex. Finally, afﬁnity is
also important because the method requires capture of endoge-
nous protein present at low levels in cell lysates and also retention
during the extensive wash steps employed after the complex has
been captured.
Ideally, the properties of high afﬁnity and recognition of native
complexed antigen in lysates should be selected during antibody
generation. Phage display provides a simple means of generating
antibodies through panning of large antibody libraries on native
immobilized antigen. In a recent study, we demonstrated that we
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Fig.3. (A–E) Immunoprecipitation of SHC1 using primary and chain-shufﬂed antibodies. Immunoprecipitation of the three isoforms of SHC1 (66, 52, and 46 kDa) from the
human breast cancer cell MDA-MB231 [33] was demonstrated using a panel of 20 unique scFvs. Immunoprecipitation was performed using anti-FLAG agarose beads (see
Materials and methods), and samples were separated by SDS–PAGE, Western blotted, and detected by polyclonal anti-SHC1 antibody. Lanes a: preimmunoprecipitation
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Fig.5. Relationship between afﬁnity or off-rate and immunoprecipitation efﬁciency. Percentage recovery of target SHC1 from lysates was calculated using ﬂuorescent
Western blots. (A and B) Plots are shown of percentage SHC1 recovered against scFv dissociation constant (A) and off-rate (B). (C) Simulation plot of log fraction bound against
time for different off-rates, assuming monovalent dissociation and no rebinding (http://www.graphpad.com/curveﬁt/dissociation_htm). Curves were ﬁtted to the equation
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to demonstrating the potential for high-throughput selection,
antibodies generated in this earlier work [17] provided the basis
for the afﬁnity maturation work described here.
We reasoned that the afﬁnity of the antibody for its target
would be a key parameter for success. To improve the afﬁnity of
clones emerging from phage display, we sought to use a scalable
method of afﬁnity maturation capable of dealing with multiple tar-
gets and multiple clones within a group of antibodies. In general,
afﬁnity maturation involves diversiﬁcation of a lead clone followed
by stringent selection from the resultant library of related binders.
For diversiﬁcation, the method of chain shufﬂing is ideally suited
not just for single clones but also for oligoclonal mixes as well as
whole populations. This approach was ﬁrst described for afﬁnity
maturing antibodies to haptens [39–41]. Here we demonstrate that
chain shufﬂing is a very effective way to afﬁnity mature several
antibody populations simultaneously to multiple protein targets.
Selected VH genes that bound only their target antigen from a
set of 20 SH2 domains were recombined with the population of
VL genes used in the initial construction of the library. In particular,
VH fragments speciﬁc to each of the eight SH2 domains were com-
bined into oligoclonal mixes for each speciﬁc antigen and crossed
with the library of VL genes used in the construction of the original
naive library [7], creating eight gene-speciﬁc libraries of 108–109
clones. After two rounds of selection with chain-shufﬂed subli-
braries, phage inhibition ELISA showed that the average afﬁnity
of the population had improved by 1–2 orders of magnitude to
the target antigen. The degree of afﬁnity enrichment was
dependent on the conditions used for the panning. In general, aﬁrst-round low-stringency panning (either antigen coated directly
on a polystyrene surface or 100 nM biotinylated antigen captured
on streptavidin beads) was performed ﬁrst to ensure capture and
ampliﬁcation of the majority of binders. This was followed by a
second-round selection using lower concentrations of biotinylated
antigen to increase stringency. As an alternative, a strategy of ‘‘off-
rate selection’’ could be employed [42] to select clones with a
slower off-rate. The process of diversiﬁcation and stringent selec-
tion led to an improvement in average afﬁnity as measured by
polyclonal ELISA using selected phage populations. After expres-
sion and puriﬁcation, many individual scFvs displayed dissociation
constants (KD values) in the low nanomolar range [1].
Sequence analysis of the chain-shufﬂed and reselected scFvs
showed that new light chain partners had been identiﬁed follow-
ing stringent selection. In some cases, the representation of input
VH genes was reduced compared with the input library. For
example, for the SHC1 selection, only 5 of the 15 different VH genes
used in the library appeared among 155 of the top-ranked clones.
Presumably, derivatives from the other 10 VH genes used in the
shufﬂed library construction could not compete with the progeny
from the top 5 VH genes. A large number of novel partners were
found to complement these 5 VH genes. Among the 155 clones
examined, the 5 VH genes were found partnered with 59 different
VL genes (using analysis of CDR3 sequence only).
Success in immunoprecipitation requires antibodies that target
epitopes that are available in native protein complexes. To focus on
antibodies with this property, we developed a 96-well plate-based
afﬁnity capture screen that enabled the screening of hundreds of
clones simultaneously for their ability to bind endogenous
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volved the directional immobilization of scFvs from crude culture
supernatants onto 96-well plates followed by incubation with cell
lysate. Captured SHC1 was detected with a rabbit anti-SHC1 poly-
clonal antibody. There was a strong correlation between success in
the high-throughput afﬁnity capture assay and the ability of an
antibody to perform in immunoprecipitation. The assay could be
used for other targets provided that a polyclonal detecting anti-
body was available. Potentially, the selected polyclonal phage pop-
ulation from which the test antibody arose could itself sufﬁce for
detection of captured target. It is interesting to note that only a
minority (12%) of afﬁnity matured scFvs were successful in the
afﬁnity capture assay, and this is likely due to a combined require-
ment for afﬁnity and the need to recognize available epitopes on
native protein.
Each group of antibodies sharing a VH gene partnered with dif-
ferent VL genes can be regarded as a clan that is likely to share a
common epitope (especially given that the target antigen is only
110 amino acids on average), giving the opportunity to examine
the effect of afﬁnity on immunoprecipitation independent of epi-
tope. A relationship was observed between immunoprecipitation
success and afﬁnity, as shown by selecting 10 anti-SHC1 scFvs
and measuring their on- and off-rates by SPR. For both clan 3
and clan 5 (see Supplementary Table 1), there are examples
where the original unshufﬂed clones failed or were inefﬁcient in
immunoprecipitation, but afﬁnity maturation by chain shufﬂing
produced higher afﬁnity clones capable of afﬁnity capture of
SHC1 from lysates. Plotting the proportion of SHC1 captured in
immunoprecipitation, quantitated from ﬂuorescent Western blot
against either equilibrium dissociation constant (KD) or dissocia-
tion rate (koff), revealed a direct relationship with a sharp cutoff
between success and failure in immunoprecipitation. For clan 5,
the cutoff was a KD of less than 60 nM and a koff of less than
0.1 s1. This can partly be explained by the long wash steps em-
ployed during an immunoprecipitation experiment, and as shown
in Fig. 5C (modeled assuming monovalent binding and a simple
exponential decay curve), small changes in the off-rate can have
large effects on the proportion of target that remains associated
with the capture antibody. The situation may be more complex
where proteins are part of a multisubunit signaling complex,
avidity effects lengthen the antibody/antigen half-life, and rebind-
ing occurs [42], but the beneﬁcial effect of increased off-rate is
nonetheless clear.
For clans 1, 2, 3, and 5, none of the parental clones was reselect-
ed following shufﬂing. However, parental clones did appear in
selection 72 for clan 4. Here 14 of 41 clones were parental, as
judged by having an identical VL CDR3 sequence. This included
clone 72_1A10, which displayed good afﬁnity for SHC1 (KD =
25 nM) and was used successfully in immunoprecipitation. For this
clan, it is clear that good antibodies were already identiﬁed from
the primary selection. However, for clans 3 and 5, it is also clear
that afﬁnity maturation by chain shufﬂing was an absolute
requirement to transform an antibody with low afﬁnity and a
failure (or poor performer) as an immunoprecipitation reagent into
a higher afﬁnity antibody that was competent to pull down
endogenous levels of a target protein. Clans 1 and 2 are examples
where chain shufﬂing and reselection failed to result in
immunoprecipitation competent antibodies. Depending on the
diversity of the initial phage antibody library, and on the presence
of antibodies in that library that are able to bind a given epitope
with sufﬁcient afﬁnity for endogenous immunoprecipitation, there
is a strong argument to perform the population-based afﬁnity mat-
uration by chain shufﬂing described in this article both to increase
the probability of identifying useful antibodies and to increase the
number of immunoprecipitation competent antibodies able to bind
to different epitopes.Conclusion
We have presented a scalable method for antibody afﬁnity mat-
uration, based on chain shufﬂing, to generate improved phage anti-
bodies to a set of eight SH2 domain proteins. For each antigen, we
matured oligoclonal mixes of clones that previously had been
shown to have exquisite speciﬁcity for the target antigen, and we
demonstrated that it is possible to rapidly and simultaneously
afﬁnity mature multiple speciﬁc antibodies to multiple different
antigens. Using an afﬁnity capture screen, we found that only a
minority of afﬁnity matured scFvs were successful in the capture
of target antigens from lysates, and this is likely due to a combined
requirement for afﬁnity and the need to recognize available epi-
topes on native protein. Afﬁnity improvements were a key deter-
minant in the success of immunoprecipitation demonstrated
using panels of antibodies with differing afﬁnities to the same epi-
tope. This systematic approach not only illustrated the importance
of afﬁnity but also identiﬁed a relatively sharp cutoff distinguish-
ing between success and failure. Finally, we validated this ap-
proach by combining afﬁnity capture using matured antibodies
with MS to identify seven binding partners of SHC1 in EGF-stimu-
lated cells. This approach, combined with MS, will help to advance
our knowledge and understanding of protein interactions occur-
ring during cell signaling.
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